Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance

Guardant Health, Inc.

2026-Q1 EPS reported -$0.85 revenue$301,665,000

Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.
Net loss per share widened to $0.85 from $0.77; non-GAAP net loss per share improved to $0.45 from $0.49.
Raised 2026 revenue guidance to $1.30-$1.32B (32-34% growth), up from prior $1.25-$1.28B; Oncology volume growth expected >35%.
Shield screening tests reached 44,000 in Q1; 2026 Shield volume guidance raised to 230,000-245,000 tests.
Q1 adjusted EBITDA loss of $58.9M relatively flat; free cash flow burn $71.2M; cash position $1.2B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardant Health, Inc. reported the quarter ended March 31, 2026 results: revenue $301.7 million. Guidance raised.

Period: the quarter ended March 31, 2026
Revenue: $301.7 million
Guidance: raised
Result: reported results

Exact text from the filing

March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-26-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.